A 3-year survey is reported of acute poisoning by Wright's Vaporizing Fluid which covered a change in formulation from 90°/ cresol to 10%y chlorocresol.
Introduction
Wright's Vaporizing Fluid (Wright, Layman and Umney Ltd) is 'recommended for the relief of soreness and congestion of the upper respiratory tract'. It is administered by volatilization over a night-light in a purpose built 'vaporizer', producing a vapour which circulates throughout the room. The fluid itself is cresolic and the vapour, therefore, possesses a powerful 'antiseptic' smell. It is sold in 50-ml bottles from which 10-ml portions are to be introduced into the vaporizer.
When used as instructed the vapour is apparently free from serious adverse effects, but if the unvolatilized fluid is ingested accidentally or deliberately, it is toxic and thus may result in acute poisoning. The product has always carried a clear warning label in red lettering, but nevertheless the National Poisons Information Service (NPIS) has received many enquiries for advice in the treatment of its ingestion. There is an impressive report in the literature of a case of a 12-month-old child who died apparently from absorption of cresol after the fluid had been spilt over his head (Green, 1975) 
Methods
Details were recorded of the age of the patient, the amount of fluid ingested, the formulation involved, the signs and symptoms at the time of the original telephone call. Further details of treatment and outcome were then sought by writing to the clinician concerned in each instance. Each case was classified according to the severity of symptoms and signs.
Type A: superficial skin burns only (on hands, fingers, face and lips) from liquid having been spilt, but with no definite evidence of ingestion.
Type B: inflammation and a burning sensation in the mouth and throat, sometimes vomiting, abdominal pain and dysphagia lasting some days.
Type C: severe poisoning often with blistering and ulceration of the oral mucosa, oedema of the pharynx and glottis, salivation and coughing, abdominal pain, vomiting, haematemesis, dyspnoea, pneumonia, cough and collapse.
Type C cases may also show phenolic staining of the urine with evidence of liver and kidney damage.
Results
During the 3-year survey 311 cases were reported to the NPIS, 286 involving children. Type B symptoms were described in 54 and type C symptoms in 12. Follow-up information was received for 160 children aged between 2 months and 9 years (average age, 2 5 years) and 12 adults aged between 14 and 75 years (average age, 34 years). Further discussion will be confined to those cases where follow-up information is available.
Among those followed-up, 31 children and 6 adults had type B symptoms, while 11 children and 2 adults had type C symptoms (Table 1) . One child died, but all other cases recovered without long-term effects. Since January 1977 it has been possible to discover the formulation involved in just over 70% of the cases where follow-up information was received. 
Discussion
Cresol and chlorocresol are phenol derivatives which are caustic and exert their toxic effects directly on all cells by denaturation and precipitation of proteins. In small amounts they have salicylate-like stimulating effects on the respiratory centre, which causes respiratory alkalosis followed by acidosis due to uncompensated renal loss of base during the alkalosis, partly due to the acidic nature of the phenolic radical and partly from derangements in carbohydrate metabolism. They are excreted in the urine and after large doses renal damage is likely (Dreisbach, 1977) .
Treatment is essentially supportive. After spillage, the skin should be washed well with water for up to 15 min followed by repeated application of castor Since it appears that even the new formulation can cause serious problems it is pertinent to consider measures which may help to prevent further cases of acute poisoning. These might include child-resistant containers (CRC), improved labelling, unit dose packaging and altered formulation. When they discussed this report with the manufacturers the authors were informed that a CRC would be introduced forthwith and that the other measures, although much more complex, would be considered. In the meantime it is hoped that this paper will bring the problem to the attention of doctors and pharmacists and that awareness of the problem will help to prevent further accidents. The authors will continue to monitor any further cases reported to them and hope to include a study of the urinary excretion of cresol and chlorocresol.
